Status:
COMPLETED
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Urinary Incontinence
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
Eligibility Criteria
Inclusion
- Subjects with a diagnosis of overactive bladder.
Exclusion
- Subjects with significant stress incontinence as determined by the investigator.
- Subjects with recurrent urinary tract infections defined as treated for UTI; 5 times in the last year.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2006
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00139724
Start Date
May 1 2005
End Date
October 1 2006
Last Update
January 27 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100020
2
Pfizer Investigational Site
Beijing, Beijing Municipality, China, 100034
3
Pfizer Investigational Site
Huangzhou, Zhejiang, China, 310003
4
Pfizer Investigational Site
Beijing, China, 100034